Gynécologie - Col utérus SENTICOL III International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer Paris, Saint-Cloud VIRGINIE FOURCHOTTE, VIRGINIE FOURCHOTTE
Sein métastatique RH+ DOLAF An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib Saint-Cloud
VADS NIVOPOST-OP / GORTEC 2018-01 A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC
Sein métastatique RH+ AMBRE OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Appareil Digestif PERSPECTIVE (MS202202-0002) A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE) Saint-Cloud
VADS TrilynX (Debio 1143-SCCHN-301) A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in;combination with platinum-based chemotherapy and standard fractionation intensitymodulated;radiotherapy in patients with locally advanced squamous cell carcinoma of;the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Paris CHRISTOPHE LE TOURNEAU
VADS INTERMEDIATE-01 Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy Saint-Cloud CAMILA LEITE NASCIMENTO
VADS MK7902-009 (LEAP-009) Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) Paris CHRISTOPHE LE TOURNEAU